Prilenia Therapeutics Israeli Company

Prilenia is a late clinical-stage biotechnology company founded in 2018 focused on the urgent mission to develop novel therapeutics to address the progression of neurodegenerative diseases and neurodevelopmental disorders. The initial focus of the company has been on Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS). ​